NCT06626932

Brief Summary

To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
259

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Oct 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Oct 2024Nov 2026

First Submitted

Initial submission to the registry

September 27, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 4, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

October 4, 2024

Status Verified

September 1, 2024

Enrollment Period

2 years

First QC Date

September 27, 2024

Last Update Submit

October 2, 2024

Conditions

Keywords

18-f FDG PET/CT

Outcome Measures

Primary Outcomes (1)

  • PET/CT scan on cancer patient will be performed to evaluate the biological and procedural factors of 18-f FDG uptake by multiple normal organs and neoplastic lesions using Standardized uptake values

    SUV mean , suv peak and suv max

    2 years

Interventions

Eligibility Criteria

Age1 Year - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

all cancer patients

You may qualify if:

  • cancer patients referred to nuclear medicine unit

You may not qualify if:

  • patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Asyut, Egypt

Location

MeSH Terms

Interventions

Fluorodeoxyglucose F18

Intervention Hierarchy (Ancestors)

DeoxyglucoseDeoxy SugarsCarbohydrates

Central Study Contacts

Mahenoor Alaa Abouelouon, Master

CONTACT

nadia mohany mostafa, assistant professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

September 27, 2024

First Posted

October 4, 2024

Study Start

October 1, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

October 4, 2024

Record last verified: 2024-09

Locations